Susan Levinson

Initial Funding Effort to Advance Recombinant Plasma Gelsolin Therapy into Human Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that it has closed its final tranche of an $8MM convertible note round. These funds will be used to advance its clinical program into human clinical trials in severe …

December 3, 2014: BioAegis Therapeutics Closes Successful $8MM Convertible Note Round Read More »

Patent Covers Therapeutic Uses of Plasma Gelsolin in Renal Failure BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that its portfolio of patents has been expanded with the granting of a second European Patent for plasma gelsolin. Claims in this patent are directed to the treatment of renal failure.

Initial Effort to Elucidate the Role of Plasma Gelsolin in Human Diseases with Significant Inflammatory and Infectious Disease Complications BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics has announced that it has entered into a research collaboration with the National Institute of Allergy and Infectious Diseases. NIAID, which is one …

November 10, 2014: BioAegis and the National Institute of Allergy and Infectious Diseases (NIAID) Enter into Research Collaboration Read More »

Company To Sponsor Phase 2 Trials in Community-Acquired Pneumonia in Europe BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics reports that its clinical program was well-­received by two EU regulatory authorities, the MHRA in the United Kingdom and the MPA in Sweden. After completion of required preparatory work the company …

November 10, 2014: BioAegis Therapeutics Seeks Advice from MHRA and MPA in Anticipation of European Phase 2 Clinical Studies Read More »

Company to enter Full-Scale cGMP Production for Clinical Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today it has completed its engineering manufacturing run and is preparing to launch its manufacture of clinical supplies. The campaign to produce recombinant protein in E. coli was successful and generated higher …

November 28, 2013: BioAegis Therapeutics Completes Engineering Run of High-Yield Recombinant Plasma Gelsolin Read More »

Company to Manufacture Clinical-Grade Supplies for Forthcoming Clinical Trial in Community-Acquired Pneumonia BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 26, 2013) BioAegis Therapeutics announced that it has engaged Debra Barngrover Ph.D. to oversee the company’s recombinant manufacturing of plasma gelsolin. Dr. Barngrover is a pharmaceutical process development expert with extensive experience in protein …

November 26, 2013: BioAegis Therapeutics Engages Debra Barngrover to Oversee Recombinant Manufacturing of Plasma Gelsolin Read More »

Company to Evaluate Orphan Diseases as Secondary Indications BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 28, 2013) BioAegis Therapeutics announced that the FDA has transferred Orphan Designations for cystic fibrosis and bronchiectasis to the company. The FDA Office of Orphan Products Development (OOPD) provides support and incentives for sponsors to develop products for …

July 28, 2013: FDA Transfers Orphan Drug Designation for Cystic Fibrosis and Bronchiectasis to BioAegis Therapeutics Read More »

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 26, 2013) BioAegis Therapeutics announced today that a patent has been granted in Japan that that covers the diagnostic claims of the therapeutic and diagnostic application. Further Japanese applications for therapeutic claims in inflammation are pending.

Bolognese to Provide Statistical Design of Biomarker-Driven Phase 2b Human Efficacy Study in Severe Community-Aquired Pneumonia BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – June 15, 2013) BioAegis Therapeutics announced today that it has engaged Jim Bolognese, Senior Director of Strategic Consulting at Cytel Inc., a leading firm in the design and conduct of adaptive …

June 15, 2013: BioAegis Therapeutics Engages Jim Bolognese, Senior Director of Strategic Consulting at Cytel Read More »

Supplies to be Used in Forthcoming Human Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – April 15, 2013) BioAegis Therapeutics announced today that it has engaged the Billingham, UK group of Fujifilm Diosynth—a first-tier contract biologics manufacturer, to manufacture clinical-grade supplies of recombinant human plasma gelsolin, the body’s 4th most abundant plasma protein that …

April 15, 2013: BioAegis Therapeutics Engages FujiFilm Diosynth Biotechnlogies to Manufacture Clinical-Grade Supply of Recombinant Human Plasma Gelsolin Read More »